Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems

Medical Oncology

Volumn 34, Issue 4, 2017, Pages

  Xiong, Yi ^c   Huang, Bi Yun ^b   Yin, Ji Ye ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Central South University   (China)

Author keywords

Cisplatin; DNA repair pathway(s); Drug response; Single nucleotide polymorphism(s); Survival

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; DOUBLE STRANDED DNA; ENDONUCLEASE; ESTERASE; EXCISION REPAIR CROSS COMPLEMENTING ENZYME GROUP 5; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN; PLATINUM COMPLEX;

CANCER CHEMOTHERAPY; DNA REPAIR; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; EVIDENCE BASED PRACTICE; EXCISION REPAIR; GENETIC VARIABILITY; HEREDITY; HUMAN; MISMATCH REPAIR; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; PHARMACOGENETICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85013218992     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-017-0905-6     Document Type: Review

References (97)

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709–19.
2. Khuri FR. Lung cancer and other pulmonary neoplasms. In: Lee G, Andrew IS, editors. Goldman-cecil medicine. 25th ed. New York: Saunders; 2016. p. 1303–13.
3. Tieche CC, Peng RW, Dorn P, Froment L, Schmid RA, Marti TM. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC Cancer. 2016;16(1):125.
4. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Cancer Netw. 2016;14(3):255–64.
5. Kuribayashi K, Funaguchi N, Nakano T. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. J Cancer Res Ther. 2016;12(2):528–34.
6. Macerelli M, Ganzinelli M, Gouedard C, Broggini M, Garassino MC, Linardou H, et al. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev. 2016;48:8–19.
7. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.
8. D’Antonio C, Milano A, Righini R, Onesti CE, Bassanelli M, Falcone R, et al. Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. Anticancer Res. 2014;34(10):5241–50.
9. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metabol Toxicol. 2009;5(7):745–55.
10. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol. 2012;9(3):144–55.
11. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–50.
12. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2012;14(1):23–34.
13. Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res. 2011;17(22):6973–84.
14. Bonanno L, Favaretto A, Rosell R. Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Res. 2014;34(1):493–501.
15. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78.
16. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287–94.
17. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
18. Choi JY, Park JM, Yi JM, Leem SH, Kang TH. Enhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents. Oncotarget. 2015;6(26):22575–86.
19. Cleaver JE, Lam ET, Revet I. DNA repair: from genome maintenance to biomarker and therapeutic target. Nat Rev Genet. 2009;10(11):756–68.
20. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004;14(6):959–70.
21. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000;60(9):1305–13.
22. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108(8):1695–703.
23. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.
24. Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, et al. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Investig. 2010;28(10):1078–83.
25. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368(12):1101–10.
26. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol. 2012;7(6):973–81.
27. Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, et al. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol Rep. 2013;30(5):2385–98.
28. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol. 2011;6(12):2018–26.
29. Du Y, Su T, Zhao L, Tan X, Chang W, Zhang H, et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS ONE. 2014;9(6):e99843.
30. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56(2):281–8.
31. Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15(3):159–66.
32. Li D, Zhou Q, Liu Y, Yang Y, Li Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol. 2012;29(3):1622–8.
33. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4945–52.
34. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.
35. Wei HB, Hu J, Shang LH, Zhang YY, Lu FF, Wei M, et al. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J (Engl). 2012;125(16):2902–7.
36. Yu D, Shi J, Sun T, Du X, Liu L, Zhang X, et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol. 2012;33(3):877–84.
37. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE. 2012;7(6):e38150.
38. Huang D, Zhou Y. Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed Rep. 2014;2(4):452–62.
39. Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene. 2013;526(2):265–74.
40. Yin JY, Li X, Zhou HH, Liu ZQ. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics. 2016;17(12):1365–78.
41. Sullivan I, Salazar J, Majem M, Pallares C, Del RE, Paez D, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353(2):160–6.
42. Huang SJ, Wang YF, Jin ZY, Sun JY, Guo ZL. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Tumour Biol. 2014;35(5):4023–9.
43. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer. 2005;4(1):18.
44. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res. 2002;62(19):5457–62.
45. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect. 2003;111(15):1843–50.
46. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118(9):2466–75.
47. Provencio M, Camps C, Cobo M, De Las PR, Massuti B, Blanco R, et al. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol. 2012;70(6):883–90.
48. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres JM, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer. 2011;71(2):191–8.
49. Zhou M, Ding YJ, Feng Y, Zhang QR, Xiang Y, Wan HY. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genet Mol Res. 2014;13(2):3310–8.
50. Li P, Wang Y, Cheng J, Chen J, Ha M. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen. Tumor Biol. 2015;36(12):9465–73.
51. Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, et al. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies. PLoS ONE. 2013;8(11):e79864.
52. Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, et al. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8(8):e72251.
53. Li XD, Han JC, Zhang YJ, Li HB, Wu XY. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev. 2013;14(1):145–8.
54. Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, et al. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS ONE. 2012;7(3):e33200.
55. Chen X, Sun H, Ren S, Kim CV, Zhang L, Zhou S, et al. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol. 2012;14(3):207–13.
56. Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 2014;346(2):163–71.
57. Liu D, Wu J, Shi GY, Zhou HF, Yu Y. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. Genet Mol Res. 2014;13(2):3100–7.
58. Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res. 2014;13(3):7617–25.
59. Yuli Y, Zhe S, Xia W, Siqing L, Zhenxuan W, Yu-Hua Z, et al. XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer. Pak J Med Sci. 2013;29(3):762–7.
60. Zhang T, Sun J, Lv M, Zhang L, Wang X, Ren JC, et al. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy. Asian Pac J Cancer Prev. 2013;14(2):701–5.
61. He C, Duan Z, Li P, Xu Q, Yuan Y. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs. 2013;24(3):300–5.
62. Jordheim LP, Seve P, Tredan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 2011;12(7):693–702.
63. Mlak R, Krawczyk P, Ciesielka M, Koziol P, Homa I, Powrozek T et al. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. Clin Trans Oncol. 2016;18(9):915–924.
64. Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, et al. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer. 2013;82(2):288–93.
65. Liu Y, Bernauer AM, Yingling CM, Belinsky SA. HIF1alpha regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis. 2012;33(6):1187–92.
66. Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, et al. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method. Technol Cancer Res Treat. 2013;12(5):473–82.
67. Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 2009;41(5):429–35.
68. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31(19):5526–33.
69. Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, et al. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2013;71(5):1287–95.
70. Yuan Z, Li J, Hu R, Jiao Y, Han Y, Weng Q. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. Sci Rep. 2015;5:16482.
71. Gu AQ, Wang WM, Chen WY, Shi CL, Lu JH, Han JQ. XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects. Int J Clin Exp Med. 2015;8(1):145–54.
72. Li L, Wan C, Wen FQ. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis. Genet Mol Res. 2014;13(2):3772–86.
73. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res. 2012;18(14):3972–81.
74. Chen J, Zhao QW, Shi GM, Wang LR. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B. 2012;13(11):875–83.
75. Zhao R, Chen G. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(11):14909–16.
76. Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, et al. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer. 2014;135(11):2687–96.
77. Jeggo PA, Lobrich M. How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability. Biochem J. 2015;471(1):1–11.
78. de Las PR, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17(4):668–75.
79. Shen XY, Lu FZ, Wu Y, Zhao LT, Lin ZF. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. PLoS ONE. 2013;8(8):e69553.
80. Qiu M, Xu L, Yang X, Ding X, Hu J, Jiang F, et al. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer. PLoS ONE. 2013;8(10):e77005.
81. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92.
82. Deng Q, Sheng L, Su D, Zhang L, Liu P, Lu K, et al. Genetic polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer risk in a population of southeast China. Med Oncol. 2011;28(3):667–72.
83. Xu JL, Hu LM, Huang MD, Zhao W, Yin YM, Hu ZB, et al. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Asian Pac J Cancer Prev. 2012;13(3):851–6.
84. Sawant A, Kothandapani A, Zhitkovich A, Sobol RW, Patrick SM. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Repair (Amst). 2015;35:126–36.
85. Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, et al. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA. 1996;93(13):6443–7.
86. Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res. 2010;16(4):1206–15.
87. Cheng H, Sun N, Sun X, Chen B, Li F, Feng J, et al. Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochim Biophys Sin. 2010;42(5):311–7.
88. Xu XL, Yao YL, Xu WZ, Feng JG, Mao WM. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Genet Mol Res. 2015;14(2):3525–33.
89. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database Syst Rev. 2015;10:D10463.
90. John Wiley & Sons, Inc. About cochrane reviews. 1999. http://www.cochranelibrary.com/about/about-cochrane-systematic-reviews.html. Accessed 11 Oct 2016.
91. Haynes RB. Of studies, syntheses, synopses, summaries, and systems: the “5S” evolution of information services for evidence-based health care decisions. ACP J Club. 2006;145(3):A8.
92. Muzzey D, Evans EA, Lieber C. Understanding the basics of NGS: from mechanism to variant calling. Curr Genet Med Rep. 2015;3(4):158–65.
93. Coleman C, Quinn EM, McManus R. Quality control procedures for high-throughput genetic association studies. Methods Mol Biol. 2015;1326:203–15.
94. Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y, et al. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2012;18(19):5507–14.
95. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.
96. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res. 2014;20(10):2553–68.
97. Yu KH, Ricigliano M, Hidalgo M, Abou-Alfa GK, Lowery MA, Saltz LB, et al. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res. 2014;20(20):5281–9.